Actavis buys Warner Chilcott for $8.1bn
Executive Summary
Specialty pharmaco Actavis Inc. has acquired publicly traded Warner Chilcott PLC (generics) in a stock swap valued at $8.1bn, including the assumption of $3.4bn of debt. The combined company is expected to adopt the name Actavis PLC and will be led by the current Actavis team. WC shareholders will get 0.160 shares of Actavis (equal to $18.62, a 7% premium) for each share they own; WC investors will hold 23% of the new company, which will be located in Ireland and is expected to trade on the NYSE.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Topical Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice